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Metallothioneins (MT) are highly conserved
proteins that are expressed in all eukaryotes,
including plants, yeast, worms, ﬂies, and ver-
tebrates. Four major isoforms, MT-I, MT-II,
MT-III, and MT-IV, are known to exist. The
two isoforms MT-I and MT-II are ubiqui-
tously expressed, heavy metal–binding pro-
teins. MT-III expression is unique to the brain
and reproductive organs, whereas MT-IV
expression is confined to the stratified squa-
mous epithelium of skin, tongue, and intesti-
nal lining. Unlike the constitutively expressed
MT-III and MT-IV, MT-I and MT-II are co-
ordinately regulated and are highly inducible
by a variety of agents, including heavy metals,
reactive oxygen species, ultraviolet radiation,
glucocorticoids, and lipopolysaccharides [for a
review, see (1–3)]. Significant induction of
MT-I and MT-II has also been reported in
the livers of Cu,Zn-superoxide dismutase
knockout mice, probably as a compensatory
mechanism to scavenge free radicals (4).
Recent study has demonstrated that MT-I
and MT-II can be induced robustly in the
liver and lung after influenza virus infection
by overlapping but distinct molecular mecha-
nisms (5). Considerable efforts have been
expended to elucidate the molecular mecha-
nisms of MT induction [for a recent review,
see (3)]. Contrary to the upregulation of MT
expression, the down-regulation of its expres-
sion has not been explored to any great extent.
The suppression of MT expression has been
observed in Rat-1 cells that overexpress the
large subunit of the protein Ku (6), by
nuclear factor I (NFI) (7), and in some cancer
cell lines and solid tumors (8,9). In this article
we present a brief summary of these observa-
tions and potential molecular mechanisms for
the suppression of MT expression under the
different conditions.
Results and Discussion
Silencing of MT-I Gene in Cancer
Cells and Probable Molecular
Mechanisms
DNA methylation in animal cells plays a
critical role in developmental process, epige-
netic silencing, aging, carcinogenesis, X
chromosome inactivation, and certain
human genetic diseases (10,11). The most
significant methylation occurs at position 5
of cytosine in the CpG dinucleotide.
Methylation within the promoter regions
invariably leads to silencing of the gene. We
explored the possibility that the suppression
of MT-I/MT-II induction in some tumor
cells may be due to promoter methylation.
Our initial study showed that MT-I gene
was not induced in mouse lymphosarcoma
cell lines (P1798) and a rat hepatoma, a
solid tumor transplanted into the hind legs
of rats. We confirmed the methylation of
MT-I gene first by re-activating the pro-
moter by 5-azacytidine (5-AzaC), a DNA-
demethylating agent (Figure 1), and by
determining the sites of methylation using
bisulfite genomic sequencing (8,9). The lat-
ter technique consists of treatment of
genomic DNA with the bisulfite reagent
that converts unmethylated cytosine to
uracil while the methylated cytosine remains
unaltered. After strand-specific polymerase
chain reaction (PCR) of the bisulﬁte-treated
DNA, uracils and methylcytosines are
ampliﬁed as thymines and cytosines (12,13).
Analysis of the methylation sites by this
technique showed that nearly all cytosines
within the CpG dinucleotides in the pro-
moter region were methylated in lymphosar-
coma cells (9) as well as in rat hepatoma
(Figure 2) (8). None of these cytosines were
methylated in the corresponding parental
tissues thymus and liver.
Recently, we have observed that MT-I
gene is not induced in the prostate cancer
cell lines PC3 and DU145, whereas the
GST-pi gene is expressed in these cells
(Figure 3). On the contrary, MT-I is
induced by cadmium in the prostate cancer
cell line LNCaP, in which GST-pi is sup-
pressed due to promoter methylation (14).
At present we do not know whether the lack
of MT-I expression in the ﬁrst two cell lines
is due to the promoter methylation or defi-
ciency of the metal regulatory transcription
factor MTF-1 or to increased activity of a
repressor (e.g., NFI). Similarly, it has been
reported that preneoplastic nodules formed
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Metallothionein (MT) promoter was methylated in rat hepatoma and in mouse lymphosarcoma
cells by methylation of cytosine within the CpG dinucleotide region. After demethylation of
MT-I promoter in mouse lymphosarcoma cells or in the transplanted rat hepatoma with 5-aza-
cytidine, a potent inhibitor of DNA methyltransferase, the promoter was activated in response
to heavy metal treatment. MT-I promoter was also suppressed in human prostate cancer lines
PC3 and DU145, probably by promoter methylation, whereas cadmium induced MT-I in the
human prostate cancer line LNCaP. In the prostate cancer lines where MT-I was suppressed,
glutathione-S-transferase-pi (GST-pi) was expressed. On the contrary, GST-pi gene was
repressed in the cell line where MT-I was induced, which suggests an inverse relationship
between MT-I induction and GST-pi expression in some prostate cancer lines. The expressions
of GST-pi and γ -glutamyl cysteine synthase were also significantly higher (5- to 12-fold) in the
lymphosarcoma cells and the hepatoma relative to the parental tissues. The higher expressions
of these two genes suggest a compensatory mechanism in the cells where the gene for the
antioxidant MT-I/II is not induced. MT-I/II may function as a growth suppressor either alone
or in concert with other factor(s), and consequently their lack of expression could facilitate the
tumor growth. In addition to suppression of MT-I/II expression by promoter methylation, the
lack of MT induction could also be brought about by nuclear factor I (NFI), probably by inter-
action with the metal transcription factor MTF-1. An inverse relationship was observed
between the level of NFI and MT-I expression in some cells, which suggests a role for NFI in
the relatively low constitutive levels of MT-I expression in these cells. Key words: 5-azacytidine,
DNA methylation, hepatoma, lymphosarcoma, metallothionein, MTF-1, NFI, transcriptional
repression. Environ Health Perspect 110(suppl 5):827–830 (2002).
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in rat liver cannot induce MT-I upon treat-
ment with cadmium. It is conceivable that
the promoter methylation may be responsi-
ble for the lack of MT induction in these
nodules, in contrast to its induction in the
adjacent normal tissue (15). We are in the
process of analyzing whether an inverse rela-
tionship exists between the expression of
GST-pi and MT-I/MT-II genes in other
tumor cells. It would be of interest to deter-
mine whether this relationship is altered
when the promoter of the suppressed gene is
activated or when the promoter of the active
gene is suppressed.
In vivo genomic footprinting analysis
showed that the MT-I promoter in the
lymphosarcoma cells and rat hepatoma was
refractory to the positive transcription factors
that included MTF-1, a key factor that recog-
nizes the metal regulatory elements (MREs)
and directs MT transcription. By contrast, the
promoter was accessible to the transcription
factors in the control tissues (8,9) after
demethylation by 5-AzaC treatment, MT
induction was regained in the tumor cells.
When the tumor that regressed after 5-AzaC
treatment was re-transplanted into new donor
rats, the MT promoter was re-methylated and
the tumor grew back. Restriction landmark
genomic scanning with the methylation-sensi-
tive enzyme Not I (16) of the liver and
hepatoma DNA showed that many genes in
addition to the MT-I gene were methylated
in the hepatoma. To explore the potential
molecular mechanisms of promoter methyla-
tion and silencing of MT-I and other genes,
we analyzed the activities/expression of
DNA methyltransferases and the methylcyto-
sine-binding proteins. The activities of both
maintenance and de novo DNA methyltrans-
ferases (DNMT-3a and -3b) were 3- to 6-fold
higher in the hepatoma than in the liver.
Immunoblot analysis demonstrated signifi-
cantly higher levels of the de novo methyl-
transferases in the tumor than in the liver. The
higher activities/levels of these enzymes are
probably responsible for the re-methylation of
completely demethylated (both strands) MT-I
promoter after re-transplantation because the
maintenance methyltransferase requires
hemimethylated DNA as substrate. Chromatin
immunoprecipitation experiments revealed
close association of the methylcytosine bind-
ing protein MeCP2 with the MT-I promoter
in the hepatoma, which suggested its role in
the silencing of this promoter.
It is noteworthy that MT-I and MT-II
belong to a select group of genes that are
hypermethylated and silenced in some cancer
cells. The expression of human MT-IIA gene
is drastically reduced in human colorectal
tumors and cell lines derived from these
tumors compared with normal tissues (17).
Further, immortalization of human cells also
causes reduction in MT expression (18).
Interestingly, the common tumor suppressor
genes (e.g., p53, Rb, and p16) are expressed
in the rat hepatoma (19). The unabated
expression of these growth suppressor genes
suggests that other growth regulatory genes
are modulated in this and other tumors.
MT-I/MT-II may have fulfilled this role,
probably in concert with other factors.
Interestingly, overexpression of MT-I has
been shown to protect the transgenic mice
from hyperplasia in the liver induced by
hepatitis B viral antigen (20). This notion is
supported by the observation that the sup-
pression of MT expression is generally con-
ﬁned to cancer cells. Further study is needed
to establish a direct role of MT as a tumor
suppressor. Recent study in our laboratory
using inhibitors of DNA methyltransferases
and histone deacetylases has shown that the
lack of MT induction in some cancer cells is
also attributable to altered chromatin
structure (21).
Probable Compensatory Mechanism(s)
to Circumvent MT Silencing
If MT is an antioxidant, the silencing of its
gene should have an adverse effect in the cells.
It was therefore of interest to explore the
possibility of the existence of a compensatory
mechanism. To address this issue, we mea-
sured the mRNA levels of GST-pi and γ -glu-
tathionyl cysteinyl synthase (the ﬁrst enzyme
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Figure 1. Northern blot analysis of MT-I gene
expression by heavy metals in hepatoma and lym-
phosarcoma cells after treatment with 5-AzaC. (A)
Hepatoma-bearing rats (3 weeks after tumor trans-
plantation) were injected intraperitoneally with
saline or 5-AzaC at a dose of 5 mg/kg body weight
on alternate days for 2 weeks. The animals were
then injected intraperitoneally with zinc sulfate
(200 µmol/kg body weight), and sacrificed after
4 hr, and total RNA was isolated from the tumors.
RNA (30 µg) was subjected to Northern blot analy-
sis with 32P-labeled random-primed MT-I cDNA or
18S rDNA. (B) Mouse lymphosarcoma cells (P1798)
grown at a density of 1 × 106/mL were divided into
four groups. One group was treated with 50 µM
ZnSO4 or 15 µM CdSO4 for 3 hr. The other group
was treated with 2.5 µM 5-AzaC for 72 hr before
treatment with ZnSO4 or CdSO4 for 3 hr. Total RNA
was isolated from the different samples, and 30 µg
from each sample was subjected to Northern blot
analysis with MT-I or glyceraldehyde-3-phosphate
dehydrogenase cDNA.
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Figure 2. Bisulﬁte genomic sequencing of MT-I promoter in rat hepatoma and host liver (A) and in mouse
lymphosarcoma cells and thymus (B). Genomic DNA isolated from the tissues or cells was subjected to
bisulﬁte treatment after our own protocol (13), and the bisulﬁte-converted DNA was subjected to nested
PCR with primers specific for rat or mouse MT-I gene. The amplified product was sequenced with the
nested PCR primers as described (9,13) using 33P-labeled dideoxy chain terminator kit (USB Corp.,
Cleveland, OH, USA). Arrows indicate the 5-methylcytosines.
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Figure 3. Lack of MT-I expression in some human
prostate cancer cell lines. Total RNA (15 µg) iso-
lated from control and 30 µM CdSO4–treated
prostate cancer cells was subjected to Northern
blot analysis with MT-I or GST-pi cDNA or
18S rDNA. RNA from Rat-1 cells that express both
MT-I and GST-pi was used as control.Environmental Health Perspectives • VOLUME 110 | SUPPLEMENT 5 | OCTOBER 2002 829
involved in the biosynthesis of glutathione).
The expressions of both genes were signifi-
cantly higher in the lymphosarcoma cells (10-
and 5-fold, respectively) and the hepatoma
(8- and 12-fold, respectively) relative to the
expression in the parental tissues (Figure 4).
The consequence of MT silencing in
some cancer cells deserves comment. It is
conceivable that the relative lack of MT-
I/MT-II expression in these cells could result
in greater availability of zinc for a variety of
zinc ﬁnger proteins that control transcription.
Another means of regulating the level of cel-
lular zinc is via the zinc transporters (22).
Analysis of both the plasma membrane zinc
effluxers (ZnT1) and influxers (ZIP2)
revealed that the zinc efﬂuxer is constitutively
expressed at a much higher level (8-fold) in
the hepatoma than in the liver, whereas the
basal level of influxer is 3-fold higher in the
liver compared with hepatoma (23). The lack
of MT expression might be beneficial when
there is increased demand for zinc in rapidly
proliferating hepatoma. However, because
MT acts as the storage form of zinc and helps
in maintaining zinc homeostasis, its absence
probably results in higher basal level of zinc
efﬂuxer expression in the hepatoma. Indeed,
the zinc content per gram wet weight in the
hepatoma is less that in the liver, as deter-
mined by atomic absorption spectra (24). A
direct link between MT-I promoter inactiva-
tion and tumorigenesis has yet to be estab-
lished. Nevertheless, the potential role of zinc
in tumor growth and its association with MT
may play a key role in controlling the growth
of at least some tumors, particularly rapidly
proliferating cancer cells.
Role of NFI as a Repressor of the
Constitutive and Induced Expression
of MT-I
Analysis of the MT-I promoter revealed
three half-sites for the binding of NFI, a
protein expressed ubiquitously in higher
eukaryotes. Distinct, highly conserved genes
encode four isoforms of NFI protein (NFI-
A, NFI-B, NFI-C, and NFI-X) in verte-
brates (25–28). The DNA-binding domain
is located in the N-terminal region, whereas
the trans-activation/repression property is
governed by the more heterogeneous C-ter-
minal end. The different isoforms of NFI
protein can function both as a positive and
negative regulator of gene expression (29).
We explored the possibility that NFI could
function as a repressor of MT-I expression
because this protein is known to down-regu-
late the expression of several genes in a cell
type–speciﬁc manner.
To investigate the effect of NFI on
MT-I expression, we performed a series of
transient transfection assays using a pro-
moter/reporter construct containing mouse
MT-I promoter-driven luciferase reporter
gene and eukaryotic vectors expressing NFI
proteins. Overexpression of the different
isoforms of NFI caused suppression of both
constitutive and heavy metal (Cd or
Zn)–induced MT-I promoter activity in
HepG2 cells (Figure 5). The extent of the
NFI-mediated inhibitory effect varied with
the isoforms used in the transfection assay,
although the expression levels of the five
isoforms used were comparable by Western
blot analysis. Electrophoretic mobility shift
assays and antibody supershift analysis
showed that the NFI family of proteins can
interact with MRE-c´ on MT promoter (7).
A mobility shift assay (Figure 6A) using
three different cell lines showed different
levels of NFI complex formation, depend-
ing upon the cell types, which was consis-
tent with the concentration of NFI in these
cells (Figure 6B). The most noteworthy
observation was the inverse relationship
between the level of NFI and MT-I expres-
sion (Figure 6C). Accordingly, mouse
embryonic stem cells that contained the
least amount of NFI expressed the highest
level of MT-I. Interestingly, the NFI-medi-
ated repression of MT-I promoter activity
did not require NFI–DNA interaction. The
lack of requirement of the NFI binding site
was confirmed by the downregulation of a)
a synthetic MT-I promoter deprived of the
NFI binding site by NFI proteins or b) nat-
ural MT-I promoter by an NFI-C deletion
mutant lacking the DNA-binding domain.
Overexpression of MTF-1 could overcome
the NFI-mediated inhibitory effects on the
constitutive and induced expression of
MT-I (7). Preliminary study did not reveal
direct interaction of MTF-1 with NFI. It is
reasonable to conclude that NFI suppresses
MT-I expression, at least in part, by
inhibiting the MTF-1 activity.
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Figure 4. Northern blot analysis of γ -glutamyl cys-
teinyl synthase catalytic subunit (γ -GCS-cs) and
GST-pi expression in Morris hepatoma 3924A.
Poly(A)+ RNA (5 µg) isolated from the rat liver and
hepatoma as well as mouse thymus and P1798
cells was subjected to Northern blot analysis with
32P-labeled cDNA for catalytic subunit of γ -glu-
tamyl cysteinyl synthase, GST-pi, or cytochrome c
oxidase 1 (COX-1).
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Figure 5. Effect of different NFI isoforms on MT-I
promoter activity. HepG2 cells were transiently
transfected with pMT-Luc (MT-I promoter–luciferase
reporter) plasmid along with expression vectors for
different NFI isoforms, as indicated. NFI-L is a rat
liver isoform, and NFI-A, -B, -C, and -X are different
mouse isoforms. The effects of NFI isoforms on
basal, cadmium-, and zinc-induced MT-I promoter
activity are presented as percentage of MT-I pro-
moter activity retained in the presence of the NFI
isoforms.
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Figure 6. (A) Electrophoretic mobility shift assay (EMSA) of NFI complex present in different cell lines.
Whole-cell extracts from Rat-1, HepG2, and mouse embryonic stem (ES) cells were allowed to bind to
32P-labeled MRE-c´ oligonucleotide in appropriate binding buffer. The DNA protein complex was then
separated by 4% SDS-PAGE and analyzed by autoradiography. Cold NFI consensus oligo at 100-fold
molar excess was used as competitor, as indicated in the ﬁgure. (B) Western blot analysis of NFI protein.
Whole-cell extracts from Rat-1, HepG2, and mouse ES cells were separated by 10% SDS-PAGE, trans-
ferred to nitrocellulose membrane, and blotted with anti-NFI antibody. (C) Northern blot analysis of MT-I
expression. Total RNA (30 µg) isolated from Rat-1, HepG2, and mouse ES cells was separated on 1.0%
agarose–formaldehyde gel, transferred to nylon membrane, and probed with 32P-labeled mouse MT-I
probe. Ethidium bromide proﬁle of 18S ribosomal RNA was used as RNA loading control.Metals Toxicity • Jacob et al.
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Concluding Remarks
Despite considerable efforts to elucidate the
molecular mechanisms for the constitutive
and induced expression of MTs, relatively lit-
tle information is available regarding the
repression of MT expression. The present
article has discussed the conditions for the
suppression of MT expression and its poten-
tial molecular mechanisms. The silencing of a
highly inducible protein such as MT-I/MT-II
in many tumor cells is of considerable inter-
est. The key issue is why it is not induced in
some of these rapidly proliferating cells. It is
convenient to discard the signiﬁcance of these
data by advocating that MT is not essential
for the cell survival. However, this article has
proposed novel ideas to explain some of these
data. These include the potential role of MT
in retarding the growth of rapidly proliferat-
ing cancer cells, probably in concert with
other growth suppressors, or lack of MT that
might facilitate the availability of free zinc for
tumor growth. Clearly, further study is
needed to address this important issue.
The observation that NFI can down-
regulate MT expression is of considerable
interest. A potential inverse relationship
between the NFI concentration in the cell
and MT-I expression is evident from this
study. There is indication that NFI inhibits
MT suppression by interfering with the
activity of the transcription factor MTF-1.
The exact mechanism for the modification
of the MTF-1 activity by NFI should now
be established.
Finally, other suppressors of MT
expression should be explored. It is known
that treatment of cells or tissues with cyclo-
heximide, a potent inhibitor of protein syn-
thesis, can robustly enhance MT expression.
The inhibitor of MT induction that was
suppressed by inhibition of protein synthesis
remains to be identified. Our preliminary
observations suggest that NFI is not related
to this inhibitor. It is important to investi-
gate the physiological and pathological con-
ditions that facilitate MT suppression and
the functional relevance of such repression.
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